OXiGENE launches significant expansion of its R&D program in ophthalmology

Waltham, Mass., December 10, 2003 OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced a significant expansion of its research and development program in ophthalmology, including plans to begin human studies in several retinal degenerative indications and to develop formulations of its lead vascular targeting agent, Combretastatin A4 Prodrug (CA4P), for local delivery to the eye.

OXiGENE determined to broaden its ophthalmic clinical program after a 35-year-old man suffering from myopic macular degeneration showed dramatic improvement following treatment with CA4P. The patient was treated this fall by clinical investigators at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. The Wilmer Eye Institute is conducting a human study of CA4P for the treatment of a related condition, wet age-related macular degeneration, or wet AMD. The trial is being led by Assistant Professor of Ophthalmology Quan Dong Nguyen, M.D., and Professor of Ophthalmology Peter Campochiaro, M.D. Although the specifics of the patient's condition excluded him from participating in the wet AMD trial, the patient was treated by these investigators under a special U.S. Food and Drug Administration (FDA) exemption.

Prior to beginning a regimen of CA4P treatments, the patient had visual acuity of 20/50 in the study eye with active leakage in both eyes that had persisted following other treatment approaches. After the patient was treated with the systemically administered CA4P, his vision has been restored to 20/20 with significantly reduced leakage in each eye.

"The clinical investigators have told us that the patient has clearly responded to CA4P and has had a significant improvement in vision," said OXiGENE President and Chief Executive Officer Fred Driscoll. "This significant improvement in visual acuity and underlying pathology seen in this first patient, together with our current understanding of the safety profile of CA4P gleaned from

Contact: Scott Solomon
Sharon Merrill Associates, Inc.

Page: 1 2 3

Related biology news :

1. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
2. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
3. OXiGENE announces phase II clinical trial of lead anti-tumor compound in thyroid cancer
4. OXiGENE, foundation fighting blindness sign research agreement for phase I/II clinical trial
5. NHGRI launches Centers for Excellence in Ethical, Legal, and Social Implications Research
6. Joslin Diabetes Center launches research section on developmental and stem cell biology
7. NIH launches first center in Nationwide Chemical Genomics Network
8. Biogeosciences.org launches
9. Clemson launches S.C. DNA Learning Center
10. Dana-Farber launches Center for Applied Cancer Science
11. STN International launches Derwent World Patents Index First View

Post Your Comments:

(Date:8/15/2019)... ... 15, 2019 , ... Make IVD tests faster, focus on ... was the message at the world's largest gathering of laboratory professionals and IVD ... Clinical Chemistry (AACC) Annual Scientific Meeting was held in Anaheim, CA, this month. ...
(Date:8/14/2019)... ... August 14, 2019 , ... Gateway Genomics , a leading developer of ... the 38th annual Inc. 500|5000 list of fastest growing private companies, in ... have been founded and generating revenue by March 31, 2015. Ranking in the list ...
(Date:8/6/2019)... (PRWEB) , ... August 06, 2019 , ... ... veterinary stem cell manufacturing with clinical, regulatory and GMP manufacturing experience. In ... Inc. (PSC). With extensive regulatory experience and one of the ...
Breaking Biology News(10 mins):
(Date:8/29/2019)... ... 28, 2019 , ... DuPont Nutrition & Biosciences will offer ... the International Baking Industry Expo, September 8 to 11, in booth 5015. DuPont ... cost and waste reduction and from maintaining freshness throughout shelf life to reformulating ...
(Date:8/23/2019)... Wis. (PRWEB) , ... August 22, 2019 , ... The ... some of the most harmful germs and pathogens on hard surfaces including E. Coli, ... leaves behind no chemical residues. For more information, visit the product page at rovingblue.com ...
(Date:8/8/2019)... FRANCISCO (PRWEB) , ... August 08, 2019 , ... ... Intelligent Virtual Agents for sales and service organizations, today announced that the ... Value Leadership Award for the IVA market . Inference will officially accept the ...
(Date:8/6/2019)... ... August 06, 2019 , ... The National Science Foundation ... a community project that will engage middle and early high school students in ... Youth-Led Citizen Science Network for Community Environmental Assessment.” Collaborative partners presenting the authentic ...
Breaking Biology Technology:
Cached News: